“I’m going to let you in on a little secret…
Do you know why a middle school loser like me was able to fulfill my dream of becoming a doctor?
It comes down to one simple truth: I don’t let my emotions dictate what I do. Too many people allow their feelings to control what they accomplish in a day. If I had done that, I would have never achieved anything. I’d be lucky just to get out of bed.
Be the master of your emotions. Don’t let them master you.”
Many people enjoy a drink without a second thought, but did you know that excessive alcohol consumption can significantly increase your risk of developing several types of cancer? It’s a hidden danger that often goes unnoticed. Here’s a breakdown of the various forms of cancer linked to heavy drinking:
Alcohol irritates the cells in your mouth and throat, making them more susceptible to carcinogens. Heavy drinkers are at much higher risk of developing cancers in these areas, especially when combined with smoking.
Drinking alcohol can damage the cells lining the esophagus, leading to DNA mutations over time. Certain genetic factors, such as deficiencies in alcohol metabolism, can further increase this risk.
Your liver is responsible for breaking down alcohol, and chronic drinking leads to inflammation, cirrhosis, and eventually liver cancer. Hepatocellular carcinoma is the most common type of liver cancer linked to alcohol abuse.
Alcohol affects hormone levels, particularly estrogen, which can contribute to an increased risk of breast cancer. Even moderate drinking can elevate this risk in women.
Excessive alcohol consumption is linked to cancers of the colon and rectum. Alcohol disrupts the way your body processes nutrients, leading to inflammation and other conditions that promote cancer development.
Chronic alcohol use can inflame the pancreas, increasing the risk of pancreatic cancer. Since this cancer is notoriously difficult to detect early, the connection to alcohol makes prevention even more critical.
The more alcohol you consume, the higher your risk of developing cancer. While occasional drinking in moderation might not significantly raise your risk, chronic and heavy drinking has been strongly linked to these cancers. To lower your risk:
Several individuals were arrested following the death of a 64-year-old American woman who used a controversial “suicide pod” in Switzerland. The device, known as Sarco, enables individuals to end their lives by releasing nitrogen gas, causing a painless death through oxygen deprivation. The incident occurred in the Schaffhausen canton near the Swiss-German border, supervised by a Swiss assisted suicide organization, The Last Resort
Authorities detained several people involved, including Florian Willet, the co-president of The Last Resort, a journalist, and others, on charges of inducing and aiding suicide. Although assisted suicide is legal in Switzerland, the use of the Sarco pod has raised questions about its compliance with safety regulations and the legality of nitrogen use in this contex
If you or a loved one is suffering there is hope:
Help is available
Speak with someone today
988 Suicide and Crisis Lifeline
Languages: English, Spanish
Hours: Available 24 hours
In my practice, I encounter many cases of first-episode psychosis, a critical period that requires thoughtful and precise intervention. The decisions made during this time can set a patient on the path to long-term recovery or, unfortunately, towards a lifetime of challenges.
There are a few guiding principles I always adhere to:
Predicting whether a patient will experience a single episode or develop a chronic condition like schizophrenia is challenging. While family history and substance use, particularly cannabis, can provide clues, there is still uncertainty.
I believe that after 6-12 months of treatment, it’s worth considering tapering the antipsychotic to the lowest effective dose, with a careful eye on any signs of relapse. Unfortunately, what I often see is that both patients and clinicians overlook the subtle signs of relapse because they’ve mutually decided to discontinue the medication. By the time I see them again, the situation has worsened.
Early psychosis treatment requires a delicate balance between managing symptoms and minimizing long-term side effects, all while keeping a close watch for signs of relapse. Careful planning is key to setting patients on the best path forward.
The FDA approved Cobenfy
Schizophrenia is a complex and debilitating mental disorder characterized by a range of symptoms, including hallucinations, delusions, cognitive deficits, and emotional dysregulation. Despite advancements in antipsychotic medications, many patients experience incomplete symptom relief and significant side effects. As a result, there is a growing interest in alternative therapeutic targets, including the muscarinic acetylcholine receptors (mAChRs).
The mAChRs are G protein-coupled receptors involved in various central nervous system functions, including cognition, learning, memory, and mood regulation. There are five subtypes of mAChRs (M1-M5), with the M1, M2, M3, and M4 subtypes playing significant roles in modulating neural activity related to schizophrenia.
The M1 receptor is primarily expressed in the cortex and hippocampus, regions crucial for cognitive processing. M1 agonists have shown promise in improving cognitive deficits and reducing psychotic symptoms in schizophrenia. Research indicates that M1 activation can enhance cholinergic neurotransmission and modulate glutamate and dopamine systems, potentially alleviating both positive and negative symptoms.
M2 receptors are predominantly found in the basal forebrain and play a role in modulating acetylcholine release. Although less studied than M1, M2 agonists may help balance neurotransmitter release, contributing to improved cognitive function and reduced psychotic symptoms.
The role of M3 receptors in schizophrenia is not as well understood as M1 and M4 receptors. However, M3 receptors are involved in various physiological processes, including insulin secretion and smooth muscle contraction. Research is ongoing to determine their potential therapeutic benefits in schizophrenia.
M4 receptors are highly expressed in the striatum, a brain region implicated in the regulation of motor control and reward processing. M4 agonists have shown potential in reducing dopaminergic hyperactivity, which is associated with positive symptoms of schizophrenia, such as hallucinations and delusions. Additionally, M4 activation may help mitigate side effects associated with conventional antipsychotics, such as extrapyramidal symptoms.
The therapeutic potential of M1-M4 muscarinic agonists in schizophrenia is an exciting area of research. Targeting these receptors may offer a novel approach to address the cognitive and negative symptoms of schizophrenia, which are often resistant to current treatments. Ongoing clinical trials and preclinical studies are crucial to understanding the efficacy, safety, and mechanisms of action of these compounds.
Conclusion The exploration of M1-M4 muscarinic agonists represents a promising frontier in the treatment of schizophrenia. By modulating cholinergic, glutamatergic, and dopaminergic systems, these agents have the potential to provide more comprehensive symptom relief with fewer side effects compared to traditional antipsychotics. Continued research and development are essential to bring these innovative treatments to clinical practice, offering hope for improved outcomes for individuals with schizophrenia.
A recent study published in JAMA Network Open investigated the relationship between semaglutide, a medication commonly used for type 2 diabetes (T2D), and the risk of opioid overdose in patients with both T2D and opioid use disorder (OUD). The researchers analyzed the health records of over 33,000 individuals, finding that those taking semaglutide had a significantly lower risk of opioid overdose compared to those using other diabetes medications. Semaglutide reduced overdose risk by as much as 58% when compared to insulin, and by 54% compared to metformin.
The findings suggest that semaglutide may have protective effects in people with OUD and T2D, although more research is needed to confirm the mechanisms behind these effects and to validate the results through clinical trials. Researchers emphasized that these promising outcomes highlight the potential therapeutic value of semaglutide beyond diabetes management, though the study faced limitations due to its observational design and the possibility of uncontrolled variables.
Further research is required to understand how semaglutide could be integrated into treatment strategies for opioid use disorder
The JAMA Network Open article titled “Factors Associated With the Availability of Medications for Opioid Use Disorder in US Jails” investigates the availability of medications for opioid use disorder (MOUD) in U.S. jails, such as methadone, buprenorphine, and naltrexone. It highlights that MOUD, which is a critical component in treating opioid use disorder (OUD), is underutilized in correctional facilities, despite its effectiveness in reducing overdose rates, withdrawal symptoms, and recidivism.
Key factors influencing MOUD availability in jails include jail size, regional location, the political landscape, and resources available in the facility. Jails in larger urban areas or those in states with Medicaid expansion are more likely to provide MOUD. Barriers such as stigma, lack of funding, and inadequate healthcare infrastructure also limit access to these medications.
The study emphasizes the importance of expanding access to MOUD in jails to address the opioid epidemic and improve public health outcomes for incarcerated populations as only 44% of jails offer MOUD in the current system.
The article Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trialreports findings from an extended observation period on the comparative effects of psilocybin and escitalopram in treating depression. Here are the key points:
Study Design: This was a 6-month follow-up of a Phase 2, double-blind, randomized controlled trial. It compared the effects of psilocybin (a psychedelic compound) and escitalopram (a common SSRI) on depression symptoms in patients with moderate-to-severe major depressive disorder (MDD).
Participants: Patients with moderate-to-severe MDD were randomly assigned to either psilocybin or escitalopram groups. Both treatments were administered in a controlled clinical setting
Primary Outcome: Depression symptom severity was measured using the QIDS-SR-16 (Quick Inventory of Depressive Symptomatology–Self-Report) scale at various time points, including baseline, during the treatment phase, and at the 6-month follow-up.
Results:
Both groups showed improvement in depression symptoms, but the psilocybin group had a greater reduction in symptoms compared to the escitalopram group.
The effects of psilocybin were found to be more rapid and sustained over the 6-month period.
Remission and Response Rates: A higher proportion of patients in the psilocybin group achieved remission and clinically significant response compared to those in the escitalopram group.
Safety and Side Effects: Both treatments were generally well-tolerated. However, psilocybin was associated with transient, mild-to-moderate side effects, mostly during the acute phase of treatment (e.g., perceptual disturbances).
Conclusion: Psilocybin demonstrated more pronounced and longer-lasting antidepressant effects compared to escitalopram at the 6-month follow-up. This suggests that psilocybin could be a viable alternative treatment for moderate-to-severe depression, but further research is necessary to confirm long-term safety and efficacy.
In my practice, I frequently see patients on Medication-Assisted Treatment (MAT) for opioid use disorder, whether it’s Suboxone or methadone, also being prescribed high-dose gabapentin—often without a clear indication for its use. This raises some serious red flags. ⚠️
While gabapentin can be useful in certain situations, we know there’s an increased risk of overdose when it’s combined with opioids, especially in those with a history of opioid use disorder. Gabapentin can suppress the central nervous system, making it more dangerous in combination with other sedating medications.
If there’s no solid reason for the prescription, it’s best to steer clear. Always prioritize safety and question if gabapentin is truly necessary in these cases. Let’s keep patient care and harm reduction at the forefront.
💡 Key takeaway: If there’s no clear indication, think twice before prescribing gabapentin to someone on MAT. Their safety depends on it.
I’ve never shared this story before, but lately, I’ve been reflecting on what it truly means to grow, to fight your inner battles, and become the best version of yourself. From the beginning, I knew that before I could serve others, I had to conquer my own demons — embark on my very own hero’s journey.
For those unfamiliar with the old way of landing a residency before the pandemic, let me tell you—it was intense. As a fourth-year med student, you would travel across the country, conducting interviews in person. The nerves of sitting in a room with a program director, explaining why you were the right fit, were real. But there’s something irreplaceable about sitting face-to-face with someone, feeling their energy, picking up on their vibe. It told you whether or not you could actually work with that person. That is something lost in today’s tele-interviews, and honestly, it’s a lesson that extends beyond medical school—it’s about life and human connection.
I vividly remember interviewing at a program where my final interview was with the director. We sat in silence for a minute as she looked over my CV. She didn’t introduce herself, didn’t ask how I was, just silence. Then, she saw the hobbies section where I had written that I enjoyed self-improvement seminars and books. Her reaction? She immediately began grilling me.
“You like reading self-help books?” she asked, and I could feel the judgment. I told her I prefer to call it ‘education,’ but in her eyes, I had already failed. She looked at me as if someone on a journey to improve themselves didn’t belong there. She ended the interview right then, essentially telling me I wasn’t cut out for her program.
At the time, I was hurt—angry, even. I felt like I had been dismissed for being human, for not being perfect. But that interaction has aged well. Today, I don’t look back with the same anger; instead, I see it as a powerful lesson.
Here’s the thing: the expectation that we should be “perfect” is a lie. We are all works in progress. None of us have it all figured out, despite what social media shows. And that’s okay—it’s something to embrace, not run from.So to anyone out there, especially future psychiatrists, remember this: your own journey matters. The process of growth never ends, and it’s the imperfections that make us human—and that’s where real strength lies.